Israel-based Silenseed, a clinical-stage biopharmaceutical company, has announced that it has signed a Joint Venture Agreement with Guangzhou Sino-Israel Bio-Industry Investment Fund LLP (GIBF). It is understood that the...
Striving for a better future, Silenseed is dedicated towards developing drugs and drug delivery platforms that create a novel treatment for solid tumors. Harnessing new scientific horizons, we are developing solutions for untreated cancers and innovative ways for RNAi drug delivery.
Phase II Clinical Trial for Pancreatic Cancer –
Currently available for stage 3 patients
For more details
Motivated by the challenges facing RNAi delivery, Silenseed has developed a novel drug delivery platform – LODER™ (LOcal Drug EluteR), which enables the insertion of RNAi therapeutic pharmaceuticals directly into the core of solid tumors
With patients in mind – Silenseed is dedicated towards developing novel drugs that harness new scientific horizons developing solutions for untreated cancers